Study: NCT02509559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranololhydrochloride
Description: oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Net Station® System and compatible Geodesic Sensor Nets®
Description: Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Net Station® System and compatible Geodesic Sensor Nets®
Description: Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VITAPORT
Description: Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VITAPORT
Description: Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ergoselect II 100/200
Description: Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ergoselect II 100/200
Description: Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SpiroScout
Description: Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpiroScout
Description: Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mobil-O-Graph® PWA
Description: Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobil-O-Graph® PWA
Description: Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saliva collection
Description: Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saliva collection
Description: Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase